Roxana Mehran, ESC 2021 – the PARADISE-MI Trial
Dr Roxana Mehran (Director of Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine, Mount Sinai Hospital, New York City, NY, USA) kindly shared her thoughts on the the PARADISE-MI trial (NCT02924727) from from the virtual ESC Congress 2021.
Questions
- What has been the impact of angiotensin receptor-neprilysin inhibitors (ARNIs) on the treatment of heart failure, and what unanswered questions remain? (0.13)
- What were the aims and design of the PARADISE-MI trial? (1.43)
- What were the secondary outcomes, and how well were they achieved? (3.23)
- What did you discover about coronary events after acute myocardial infarction? (5.14)
- What do you think will be the focus of research going forward? (8.50)
Speaker disclosures: Dr Roxana Mehran reports institutional research grants from Abbott, Abiomed, Applied Therapeutics, Arena, AstraZeneca, Bayer, Biosensors, Boston Scientific, Bristol-Myers Squibb, CardiaWave, CellAegis, CERC, Chiesi, Concept Medical, CSL Behring, DSI, Insel Gruppe AG, Medtronic, OrbusNeich, Philips; personal fees from ACC, Cine-Med Research, WebMD, SCAI; consulting fees paid to the institution from Abbott, Abiomed, AM-Pharma, Alleviant Medical, Bayer, Beth Israel Deaconess, CardiaWave, CeloNova, Chiesi, Concept Medical, CSL Behring, DSI, Duke University, Idorsia Pharmaceuticals, Medtronic, Novartis, Philips; Equity <1% in Applied Therapeutics, Elixir Medical, STEL, CONTROLRAD (spouse); Scientific Advisory Board for AMA, Biosensors (spouse); Faculty CRF (no fee)..
Support: Interview and filming supported by Touch Medical Media and conducted by Heather Hall.
Filmed during a remote video call with Dr Roxana Mehran as a highlight of ESC 2021, September 2021.